Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A drug support and preparation method thereof

A technology on drugs and stents, which is applied in the field of drug stents and its preparation, can solve problems such as vascular restenosis, achieve the effects of delaying endothelial repair, reducing endothelial cell growth inhibition, and shortening the time of antithrombotic and platelet drugs

Active Publication Date: 2021-03-12
SHANGHAI MICROPORT MEDICAL (GROUP) CO LTD
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] The invention provides a drug stent and a preparation method thereof, which are used to solve the problem of vascular restenosis after PCI

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A drug support and preparation method thereof
  • A drug support and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0035] Experimental Example 1: Cell Experiment

[0036] A drug preparation:

[0037] (1) Amlexanox group:

[0038] a) Before the experiment, the drug stent loaded with amlexanox was placed in DMSO solution, and after it was completely dissolved, it was further diluted to form a drug concentration of 10 -2 mmol / ml solution.

[0039] b) add 10 -2 The drug solution of mmol / ml was diluted with dimethyl sulfoxide (DMSO) to a concentration of 10 -3 ,10 -4 ,10 -5 , 10 -6 ,10 -7 ,10 -8 ,10 -9 mmol / ml drug solution.

[0040] c) After dispensing the series of concentration drug solutions prepared above, store them temporarily at -20 degrees Celsius for later use.

[0041] d) When in use, dilute the stored DMSO for 10 -2 ~10 -9 After the amlexanox was taken out and returned to normal temperature, the drug solution of each concentration was diluted 1000 times with the corresponding complete cell culture medium to carry out the cell test, that is, the final use concentration w...

Embodiment 2

[0060] Embodiment 2 Carrier drug stent

[0061] Mix 50mg of amlexanox, 50mg of paclitaxel, 50mg of sirolimus, 50mg of aspirin and 500mg of PLGA in 100ml of acetone. After the solute is completely dissolved, spray the solution evenly on the L605 cobalt-chromium alloy metal stent by ultrasonic atomization On the surface of the body, the total drug loading of the four drugs reaches 130μg / cm 2 . The drug stent is prepared after the solvent is completely evaporated at room temperature.

Embodiment 3

[0062] Embodiment 3 Carrier-free drug stent

[0063] Fine lines are formed on the surface of the stainless steel stent body through friction treatment, and the micronized amlexanox, paclitaxel, sirolimus, and aspirin are placed in a high-pressure airtight place with the stent body at a weight ratio of 2:1:1:1. In the equipment, turn on the equipment, so that the drug particles are embedded in the fine lines of the stent body, and the total drug loading amount reaches 160μg / cm 2 , the average particle diameter of the drug particles is not more than 1 micron, and the drug stent is obtained.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle sizeaaaaaaaaaa
Login to View More

Abstract

The invention belongs to the field of medical devices, and in particular relates to a drug support and a preparation method thereof. The drug stent includes a stent body and a drug composition distributed on the stent body, and the drug composition is composed of amlexanol, paclitaxel, sirolimus and aspirin. The preparation method comprises the following steps: firstly preparing the mixed powder or solution of the pharmaceutical composition, and then loading the prepared mixed powder or mixed solution onto the surface of the stent body by dripping, filling or coating . The present invention finds that the composition of amlexanox, paclitaxel, sirolimus and aspirin has a high activity of inhibiting the proliferation of smooth muscle cells. It also has the characteristics of low endothelial cell growth inhibition, so it can prevent the incidence of vascular restenosis and will not delay endothelial repair during the treatment after PTCA.

Description

technical field [0001] The invention belongs to the field of medical devices, and in particular relates to a drug support and a preparation method thereof. Background technique [0002] Amlexanox (Amlexanox) common name: 2-amino-7-isopropyl-5-oxo-5H[1]phenylpyranyl-[2,3,-b]-pyridine-3-carbonic acid di Toluic acid, also known as CHX3673. English chemical name: 2-amimo-7-isopropyl-5-oxo-5H-[1]benzopyrano-[2,3,-b]pyridine-3-carboxylic acid. Amlexanox is an allergic reaction mediator blocker, which stabilizes the cell membrane of mast cells and inhibits their degranulation, thereby preventing the release of allergic reaction mediators and exerting an anti-allergic effect. It was first launched in Japan in 1987 for the treatment of allergic bronchial asthma. Later applied to allergic rhinitis. In 1996, Amlexanox was approved by the US Food and Drug Administration (FDA) for the treatment of oral ulcers. [0003] Amlexanol is the only prescription drug approved by the US FDA f...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61L31/16
CPCA61L31/16A61L2300/21A61L2300/216A61L2300/416A61L2300/45
Inventor 陈陆李俊菲李妍
Owner SHANGHAI MICROPORT MEDICAL (GROUP) CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com